Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy (Q38027061)

27 August 2017

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy (English)

1 reference

27 August 2017

1 reference

hepatocellular carcinoma

1 reference

1 reference

1 reference

Ching-Lung Lai

1

1 reference

PubMed ID

22806323

27 August 2017

Man-Fung Yuen

series ordinal

2

1 reference

PubMed ID

22806323

27 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

27 August 2017

1 reference

27 August 2017

57

1 reference

27 August 2017

399-408

1 reference

27 August 2017

1

1 reference

Treatment of chronic hepatitis B.

27 August 2017

1 reference

Natural history of chronic hepatitis B virus infection

21 January 2018

1 reference

Hepatocellular carcinoma in the Asia pacific region

21 January 2018

1 reference

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

21 January 2018

1 reference

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

21 January 2018

1 reference

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

21 January 2018

1 reference

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis

21 January 2018

1 reference

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

21 January 2018

1 reference

Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B.

21 January 2018

1 reference

Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels

21 January 2018

1 reference

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers

21 January 2018

1 reference

Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial

21 January 2018

1 reference

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

7 January 2021

Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression

1 reference

7 January 2021

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Gr

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.25937

1 reference

27 August 2017

1 reference

PubMed ID

22806323